Severe hyperlipoproteinemia(a) as a factor of rapidly progressive coronary artery disease in a young woman with heterozygous familial hypercholesterolemia
https://doi.org/10.15829/1560-4071-2019-5-72-73
About the Authors
U. V. Chubykina
National Medical Research Center of Cardiology
Russian Federation
Competing Interests: nothing to declare
Russian Federation
Moscow
Competing Interests: nothing to declare
O. I. Afanasieva
National Medical Research Center of Cardiology
Russian Federation
Competing Interests: nothing to declare
Russian Federation
Moscow
Competing Interests: nothing to declare
N. T. Khachatryan
National Medical Research Center of Cardiology
Russian Federation
Competing Interests: nothing to declare
Russian Federation
Moscow
Competing Interests: nothing to declare
N. G. Kukava
National Medical Research Center of Cardiology
Russian Federation
Competing Interests: nothing to declare
Russian Federation
Moscow
Competing Interests: nothing to declare
V. P. Vasiliev
National Medical Research Center of Cardiology
Russian Federation
Competing Interests: nothing to declare
Russian Federation
Moscow
Competing Interests: nothing to declare
M. V. Ezhov
National Medical Research Center of Cardiology
Russian Federation
Competing Interests: nothing to declare
Russian Federation
Moscow
Competing Interests: nothing to declare
References
1. Nordestgaard BG, Langsted A. Lipoprotein(a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res. 2016;57 (11):1953-75. doi:10.1194/jlr.R071233.
2. Catapano AL, Graham I, De Backer G, et al. ESC Scientific Document Group. ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37 (39):2999-3058. doi:10.1093/eurheartj/ehw272.
3. Ezhov MV, Sergienko IV, Aronov DM, et al. Diagnostics and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis. Revision VI. The Journal of Atherosclerosis and Dyslipidemias (JAD). 2017;3:5-22. (In Russ.)
4. Kastelein JJ, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36:2996-3003. doi:10.1093/eurheartj/ehv370.
5. Pokrovsky SN, Afanasieva OI, Ezhov MV. Lipoprotein(a) apheresis. Curr Opin Lipidol. 2016;27 (4):351-8. doi:10.1097/MOL.0000000000000319.
Review
For citations:
Chubykina U.V., Afanasieva O.I., Khachatryan N.T., Kukava N.G., Vasiliev V.P., Ezhov M.V. Severe hyperlipoproteinemia(a) as a factor of rapidly progressive coronary artery disease in a young woman with heterozygous familial hypercholesterolemia. Russian Journal of Cardiology. 2019;(5):72-73. (In Russ.) https://doi.org/10.15829/1560-4071-2019-5-72-73
Views:
870
Email this article 